Zogenix, Inc.
Clinical trials sponsored by Zogenix, Inc., explained in plain language.
Biopharma developing treatments for rare epilepsies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for rare seizure patients: Long-Term drug safety confirmed
Disease control CompletedThis study looked at the long-term safety of a drug called fenfluramine (ZX008) for people with rare seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome. A total of 412 participants who had completed earlier studies took the drug and were monitored for side effects…
Phase 3 • Sponsor: Zogenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New migraine injector wins patient satisfaction in trial
Symptom relief CompletedThis study looked at how satisfied people with migraines were using Sumavel DosePro, a needle-free injector for migraine medication. 246 adults who already used triptan drugs took part. The goal was to see if they liked this new method better than their usual treatment.
Phase 4 • Sponsor: Zogenix, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC